Eastgate Biotech Receivables

The latest receivables for ETBI is $29K as of September 2017. That compares with $98K in the prior-year period — down 70.8% year over year. Investors often review this figure alongside Eastgate Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, ETBI's receivables moved from $98K to $29K — a 70.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eastgate Biotech's operating scale or balance-sheet position.

A receivables figure of $29K for ETBI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ETBI's receivables ($29K), review year-over-year change from $98K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.